Document:

<![CDATA[3rd Amendment to 2nd Amended & Restated Loan & Security Agreement]]>

 Exhibit 10.11 
 THIRD AMENDMENT 
 TO 

SECOND AMENDED AND RESTATED LOAN AND SECURITY AGREEMENT 
 THIS THIRD AMENDMENT to Second Amended and Restated Loan and Security Agreement (this “Amendment”) is entered into as of December 16, 2011, by and between SILICON VALLEY BANK
(“Bank”) and ALPHATEC SPINE, INC., a California corporation (“Alphatec”) and ALPHATEC HOLDINGS, INC., a Delaware corporation (“Parent” and together with Alphatec, each a “Borrower”
and collectively, “Borrowers”) whose address is 5818 El Camino Real, Carlsbad, California 92008. 

RECITALS 
 A. Bank and Borrowers have entered into that certain Second Amended and Restated Loan and Security Agreement dated as of October 29, 2010, as amended by that certain First Amendment to Second Amended
and Restated Loan and Security Agreement dated as of January 31, 2011 and certain Second Amendment to Second Amended and Restated Loan and Security Agreement dated as of August 5, 2011 (as the same may from time to time be further amended,
modified, supplemented or restated, the “Loan Agreement”). 
 B. Bank has extended credit to Borrowers for the
purposes permitted in the Loan Agreement. 
 C. Borrowers have requested that Bank amend the Loan Agreement to make certain
revisions to the Loan Agreement as more fully set forth herein. 
 D. Bank has agreed to so amend certain provisions of the Loan
Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below. 
 AGREEMENT 
 NOW,
THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:

 1. Definitions. Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the
Loan Agreement. 
 2. Amendments to Loan Agreement. 

2.1 Section 2.1.1 (Term Loan). Section 2.1.1 of the Loan Agreement hereby is amended and restated in its entirety to
read as follows: 
 “2.1.1 Term Loan. 
 (a) Availability. As of the Third Amendment Effective Date, Bank shall be deemed to have made a term loan (the “Term Loan”) to Borrower in the amount of Ten Million Dollars
($10,000,000), which Term Loan shall refinance a portion of the Revolving Line outstanding as of the day immediately preceding the Third Amendment Effective Date. 
 (b) Repayment. Borrower shall repay the Term Loan in (i) equal quarterly 

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 1 

 
installments of principal beginning January 1, 2012 and continuing on the first day of each April, July, October and January thereafter, plus (ii) monthly payments of accrued interest
beginning on January 1, 2012 and continuing on the same day of each month thereafter. Borrower’s final Term Loan payment, due on the Term Loan Maturity Date, shall include all outstanding principal and accrued and unpaid interest under the
Term Loan. Once repaid, the Term Loan may not be reborrowed. 
 (c) Prepayment. So long as no Event of Default has
occurred and is continuing, Borrower shall have the option to prepay all, but not less than all, of the Term Loan, provided Borrower (i) delivers written notice to Bank of its election to prepay the Term Loan at least ten (10) days prior
to such prepayment, and (ii) pays, on the date of such prepayment (A) all outstanding principal plus accrued and unpaid interest, (B) the Make-Whole Premium, and (C) all other sums, if any, that shall have become due and payable,
including interest at the Default Rate with respect to any past due amounts.” 
 2.2 Section 2.1.3 (Letters of
Credit Sublimit). Section 2.1.3 of the Loan Agreement hereby is amended and restated in its entirety to read as follows: 
 “2.1.3 Letters of Credit. 
 (a) Bank shall issue or have issued
Letters of Credit denominated in Dollars or a Foreign Currency for Borrower’s account. The aggregate Dollar Equivalent of the face amount of outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of
Credit Reserve) may not exceed Five Hundred Thousand Dollars ($500,000), minus (i) the sum of all amounts used for Cash Management Services, and minus (ii) the FX Reduction Amount. 

(b) If, on the Revolving Line Maturity Date (or the effective date of any termination of this Agreement), there are any outstanding
Letters of Credit, then on such date Borrower shall provide to Bank cash collateral in an amount equal to 105% of the Dollar Equivalent of the face amount of all such Letters of Credit plus all interest, fees, and costs due or to become due in
connection therewith (as estimated by Bank in its good faith business judgment), to secure all of the Obligations relating to such Letters of Credit. All Letters of Credit shall be in form and substance acceptable to Bank in its sole discretion and
shall be subject to the terms and conditions of Bank’s standard Application and Letter of Credit Agreement (the “Letter of Credit Application”). Borrower agrees to execute any further documentation in connection with the
Letters of Credit as Bank may reasonably request. Borrower further agrees to be bound by the regulations and interpretations of the issuer of any Letters of Credit guarantied by Bank and opened for Borrower’s account or by Bank’s
interpretations of any Letter of Credit issued by Bank for Borrower’s account, and Borrower understands and agrees that Bank shall not be liable for any error, negligence, or mistake, whether of omission or commission, in following
Borrower’s instructions or those contained in the Letters of Credit or any modifications, amendments, or supplements thereto. 
 (c) The obligation of Borrower to immediately reimburse Bank for drawings made under Letters of Credit shall be absolute, unconditional, and irrevocable, and shall be performed strictly in accordance with
the terms of this Agreement, such Letters of Credit, and the Letter of Credit Application. 
 (d) Borrower may request that
Bank issue a Letter of Credit payable in a Foreign Currency. If a demand for payment is made under any such Letter of Credit, Bank shall treat such demand as an Advance to Borrower of the Dollar Equivalent of the amount thereof (plus fees and
charges in connection therewith such as wire, cable, SWIFT or similar charges). 
 (e) To guard against fluctuations in
currency exchange rates, upon the issuance of any Letter of Credit payable in a Foreign Currency, Bank shall create a reserve (the “Letter of Credit Reserve”) under the Revolving Line in an amount equal to ten percent (10%) of
the face amount of such Letter of Credit. The amount of the Letter of Credit Reserve may be adjusted by Bank from time to time to account for fluctuations in the exchange rate. The availability of funds under the Revolving Line shall be reduced by
the 

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 2 

 
amount of such Letter of Credit Reserve for as long as such Letter of Credit remains outstanding.” 
 2.3 Section 2.1.4 (Foreign Exchange Sublimit). Section 2.1.4 of the Loan Agreement hereby is amended and restated in its entirety to read as follows: 

“2.1.4 Foreign Exchange. Borrower may enter into foreign exchange contracts with Bank under which Borrower commits to
purchase from or sell to Bank a specific amount of Foreign Currency (each, a “FX Forward Contract”) on a specified date (the “Settlement Date”). FX Forward Contracts shall have a Settlement Date of at least one
(1) FX Business Day after the contract date and shall be subject to a reserve of ten percent (10%) of each outstanding FX Forward Contract. The aggregate amount of FX Forward Contracts at any one time may not exceed ten (10) times
Five Hundred Thousand Dollars ($500,000), minus (i) the sum of all amounts used for Cash Management Services, and minus (ii) the Dollar Equivalent of the face amount of any outstanding Letters of Credit (including drawn but unreimbursed
Letters of Credit and any Letter of Credit Reserve). The amount otherwise available shall be reduced by an amount equal to ten percent (10%) of each outstanding FX Forward Contract (the “FX Reduction Amount”). Any amounts
needed to fully reimburse Bank for any amounts not paid by Borrower in connection with FX Forward Contracts will accrue interest at the interest rate applicable to Advances.” 

2.4 Section 2.1.5 (Cash Management Services Sublimit). Section 2.1.5 of the Loan Agreement hereby is amended and
restated in its entirety to read as follows: 
 “2.1.5 Cash Management Services. Cash Management Services. Borrower
may use an aggregate amount not to exceed Five Hundred Thousand Dollars ($500,000), minus (a) the Dollar Equivalent of the face amount of any outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of
Credit Reserve), and minus (b) the FX Reduction Amount, for Bank’s cash management services, which may include merchant services, direct deposit of payroll, business credit card, and check cashing services identified in Bank’s various
cash management services agreements (collectively, the “Cash Management Services”). Any amounts Bank pays on behalf of Borrower for any Cash Management Services will accrue interest at the interest rate applicable to Advances.”

 2.5 Section 2.2 (Overadvances). Section 2.2 of the Loan Agreement hereby is amended and restated in its
entirety to read as follows: 
 “2.2 Overadvances. If, at any time, the outstanding principal amount
of any Revolving Advances exceeds the Availability Amount (such amount being an “Overadvance”), Borrowers shall immediately pay to Bank in cash the amount of such Overadvance. Without limiting Borrowers’ obligation to repay
Bank any amount of the Overadvance, Borrowers agree to pay Bank interest on the outstanding amount of any Overadvance, on demand, at the Default Rate.” 
 2.6 Section 2.4(a) (Payment of Interest on the Credit Extensions). Section 2.4(a) of the Loan Agreement hereby is amended and restated in its entirety to read as follows: 

“(a) Interest Rates. 
 (i) Revolving Advances. Subject to Section 2.4(b), the principal amount outstanding under the Revolving Line shall accrue interest at a per annum rate equal to (i) during the
period from the Third Amendment Effective Date until the Tier 1 AQR is in effect, [***]; (ii) during the period when the Tier 1 AQR is in effect, [***]; (iii) during the period when the Tier 2 AQR is in effect, [***];
and (iv) during the period when the Tier 3 AQR is in effect, [***]; in each case, which interest shall be payable monthly. 

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 3 

 (ii) Term Loan. Subject to Section 2.4(b), the principal
amount outstanding under the Term Loan shall accrue interest at a fixed per annum rate equal to the greater of [***], which interest shall be payable monthly.” 
 2.7 Section 2.4(f) (Minimum Monthly Interest). Section 2.4(f) of the Loan Agreement hereby is amended and restated in its entirety to read as follows: 

“(f) Minimum Monthly Interest. In the event the aggregate amount of interest earned by Bank in any month on account of the
Revolving Line (exclusive of any unused line fees, or any other fees and charges hereunder) is less than the product of (x) Eighteen Million Five Hundred Thousand Dollars ($18,500,000) multiplied by (y) the quotient derived by dividing
(a) the applicable interest rate (as of any date of determination) determined in accordance with Section 2.4(a)(i), by (3) 30/360 (the “Minimum Monthly Interest”), Borrowers shall pay Bank an amount, payable on the
last day of such month, in an amount equal to the (i) Minimum Monthly Interest minus (ii) the aggregate amount of all interest earned by Bank on account of the Revolving Line (exclusive of any unused line fees, or any other fees and
charges hereunder) in such month. Without limiting the foregoing, in the event this Agreement is terminated, and/or the Obligations are accelerated, before the Revolving Line Maturity Date, Borrowers shall pay to Bank, in addition to all other
amounts due under this Agreement, all Minimum Monthly Interest payments owed through such date of termination and/or acceleration and from such date through the Revolving Line Maturity Date, calculated based upon the interest rate in effect at the
time of termination or acceleration.” 
 2.8 Section 2.4(h) (Make-Whole Premium). Section 2.4(h) hereby is
added to the Loan Agreement to read as follows: 
 “(h) Make-Whole Premium. The Make-Whole Premium when due
pursuant to the terms of Sections 2.1.1(c).” 
 2.9 Section 6.9 (Financial Covenants). Section 6.9 of the
Loan Agreement hereby is amended and restated in its entirety to read as follows: 
 “6.9 Financial Covenants.
Maintain at all times, on a consolidated basis with respect to Borrowers and their Subsidiaries: 
 (a)
Adjusted Quick Ratio. An Adjusted Quick Ratio, measured monthly, of at least [***]. 
 (b) EBITDA.
Minimum EBITDA, measured quarterly commencing with the quarter ending December 31, 2011, of at least [***]. 
 (c) Capital Expenditures. Maximum annual capital expenditures (for property, plant and equipment, and instrumentation investments), measured annually commencing with calendar year 2012, not to
exceed [***] per year.” 
 2.10 Section 12.1 (Termination of Revolving Line Prior to Revolving Line Maturity
Date). Section 12.1 of the Loan Agreement hereby is amended and restated in its entirety to read as follows: 

“12.1 Termination of Revolving Line Prior to Revolving Line Maturity Date. The Revolving Line may be terminated prior to the
Revolving Line Maturity Date by Borrowers (or any of them), effective two (2) Business Days after written notice of termination is given to Bank. Notwithstanding any such termination, Bank’s liens and security interests in the Collateral
shall continue until each Borrower fully satisfies its Obligations under the Loan Documents. If such termination is at a Borrower’s election, or at Bank’s election due to the occurrence and continuance of an Event of Default, Borrowers
shall pay to Bank, in addition to the payment of 

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 4 

 
any other expenses or fees then-owing, a termination fee (the “Revolving Line Termination Fee”) in an amount equal to (i) Fifty-Five Thousand Dollars ($55,000), if such
termination occurs after the first anniversary of the Effective Date but on or prior to the second anniversary of the Effective Date; and (iii) zero Dollars ($0.00) if such termination occurs thereafter.” 

2.11 Section 13 (Definitions). The following terms and their respective definitions hereby are amended in, or added to,
Section 13.1 of the Loan Agreement: 
 “Adjusted Quick Ratio” means a ratio of (a) the
sum of (i) Borrowers’ foreign and domestic cash; (ii) domestic Cash Equivalents held at Bank or Bank’s Affiliates (subject to a control agreement in form and content acceptable to Bank); and (iii) eighty percent
(80%) of Eligible Accounts as of any date of determination, to (b) the outstanding Obligations as of such date. 
 “Availability Amount” is (a) the lesser of (i) the Revolving Line or (ii) (x) the amount available under the Borrowing Base, plus (y) the Non-Formula Amount,
minus (b) the outstanding principal balance of any Revolving Advances. 
 “Borrowing Base”
is the sum of (a) eighty percent (80%) of Eligible Accounts (which includes domestically billed foreign Accounts receivable, provided that such Accounts are otherwise Eligible Accounts); plus (b) the lesser of (i) thirty percent
(30%) of the value of Alphatec’s Eligible Inventory (valued at the lower of cost or wholesale fair market value); (ii) Seven Million Dollars ($7,000,000); or (iii) thirty percent (30%) of total borrowing availability; in
each case, as determined by Bank from Borrowers’ most recent Transaction Report; provided, however, that Bank may decrease the foregoing percentages in its good faith business judgment based on events, conditions, contingencies, or risks which,
as determined by Bank, may adversely affect Collateral. 
 “Make-Whole Premium” is an amount
equal to four percent (4.00%) of the outstanding Term Loan if the prepayment is made on or before the first anniversary of the date hereof; three percent (3.00%) of the outstanding Term Loan if the prepayment is made on or after the first
anniversary hereof but before the second anniversary hereof; two percent (2.00%) of outstanding Term Loan if the prepayment is made on or after the second anniversary hereof but before the third anniversary hereof; one percent (1.00%) of
the outstanding Term Loan if the prepayment is made on or after the third anniversary hereof but before the Term Loan Maturity Date. 
 “Non-Formula Amount” means Revolving Advances made without regard to the Borrowing Base, in an aggregate amount not to exceed Two Million Five Hundred Thousand Dollars ($2,500,000);
provided that (i) the Non-Formula Amount may only be requested one (1) time during each of the quarters ending December 31, 2011 and March 31, 2012; (ii) in each case, must be repaid within five (5) Business Days of the
respective Funding Dates thereof; and (iii) shall no longer be available after April 5, 2012. For sake of clarity, the Non-Formula Amount may not be repaid and reborrowed, except as expressly set forth in the preceding sentence.

 “Revolving Line” is a Revolving Advance or Revolving Advances in an amount equal to Twenty
Two Million Dollars ($22,000,000). 
 “Term Loan” is a loan made by Bank pursuant to the terms
of Section 2.1.1 hereof. 
 “Term Loan Maturity Date” is October 1, 2015. 

“Third Amendment Effective Date” means December 16, 2011. 

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 5 

 “Tier 1 AQR” means the period when Borrower’s Adjusted Quick Ratio is
greater than [***], but less than or equal to [***]. 
 “Tier 2 AQR” means the period when
Borrower’s Adjusted Quick Ratio is greater than or equal to [***], but less than or equal to [***]. 

“Tier 3 AQR” means the period when Borrower’s Adjusted Quick Ratio is greater than or equal to [***].

 2.12 Exhibit D attached to the Loan Agreement hereby is replaced with Exhibit D attached hereto. 

2.13 Bank hereby waives the Events of Default that occurred due to Borrowers’ failure to comply with the requirements of
(x) Section 6.9(a) of the Loan Agreement as in effect prior to the Third Amendment Effective Date, solely for the periods ended July 31, 2011, September 30, 2011 and October 31, 2011; and (y) Section 6.9(b) of
the Loan Agreement as in effect prior to the Third Amendment Effective Date, solely for the period ended September 30, 2011. 
 3. Limitation of Amendments. 
 3.1 The amendments set forth in
Section 2, above, are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan
Document, or (b) otherwise prejudice any right or remedy which Bank may now have or may have in the future under or in connection with any Loan Document. 
 3.2 This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan
Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect. 
 4.
Representations and Warranties. To induce Bank to enter into this Amendment, each Borrower hereby represents and warrants to Bank as follows: 
 4.1 Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the
date hereof (except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct as of such date), and (b) no Event of Default has occurred and is continuing; 

4.2 Each Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan
Agreement, as amended by this Amendment; 
 4.3 The organizational documents of each Borrower delivered to Bank on the
Effective Date remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect; 
 4.4 The execution and delivery by each Borrower of this Amendment and the performance by each Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly
authorized; 
 4.5 The execution and delivery by each Borrower of this Amendment and the performance by each Borrower of
its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting such Borrower, (b) any contractual restriction with a

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 6 

 
Person binding on such Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on such Borrower, or
(d) the organizational documents of such Borrower; 
 4.6 The execution and delivery by each Borrower of this
Amendment and the performance by each Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration
with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on either Borrower, except as already has been obtained or made; and 
 4.7 This Amendment has been duly executed and delivered by each Borrower and is the binding obligation of each Borrower, enforceable against such Borrower in accordance with its terms, except as
such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors’ rights. 

5. Counterparts. This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be
deemed to constitute one and the same instrument. 
 6. Effectiveness. This Amendment shall be deemed effective upon
(i) the due execution and delivery to Bank of this Amendment by each party hereto; (ii) the due execution and delivery to Bank of updated Corporate Borrowing Resolutions by each Borrower; (iii) delivery to Bank of a Warrant to
Purchase Stock, in form and content reasonably acceptable to Bank; (iv) Borrowers’ payment of all Bank Expenses, which may be debited from any of Borrowers’ accounts with Bank; and (v) such other and further matters as Bank may
reasonably request. 
 [Balance of Page Intentionally Left Blank]

  
 Portions of
this Exhibit were omitted, as indicated by [***], and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment under Rule 24b-2 of the Securities Exchange
Act of 1934, as amended. 
  
 7 

 IN WITNESS WHEREOF, the parties hereto
have caused this Amendment to be duly executed and delivered as of the date first written above. 
  

									
	BANK:	 		 	BORROWERS:
			
	SILICON VALLEY BANK	 		 	ALPHATEC SPINE, INC.
					
	By:	 	 /s/ Derek Brunelle
	 		 	By:	 	 /s/ Dirk Kuyper

	Name:	 	Derek Brunelle	 		 	Name:	 	Dirk Kuyper
	Title:	 	Dev. Team Leader	 		 	Title:	 	President and CEO
				
		 		 		 	ALPHATEC HOLDINGS, INC.
					
		 		 		 	By:	 	 /s/ Dirk Kuyper

		 		 		 	Name:	 	Dirk Kuyper
		 		 		 	Title:	 	President and CEOSettlement Agreement and General Release

 Exhibit 10.27 
 SETTLEMENT AGREEMENT AND GENERAL RELEASE 
 THIS
SETTLEMENT AGREEMENT (including Exhibits A and B, the “Settlement Agreement”) is made and entered into as of this 30th day of December, 2011 (the “Effective Date”), by Alphatec Spine, Inc. (“Alphatec”),
on the one hand, and Cross Medical Products, LLC (“Cross”) and EBI, LLC (“EBI”), on the other hand. Alphatec, Cross, and EBI are each individually referred to herein as a “Party,” and collectively
as the “Parties.” 
 1. Recitals 
 1.1. On February 12, 2010, Cross filed an action entitled Cross Medical Products, LLC v. Alphatec Spine, Inc., Case No. SACV10-00176-MRP (MLGx) in the United States District Court for the
Central District of California (the “License Action”). 
 1.2. In the License Action, Cross alleged that
Alphatec had breached an April 23, 2003, License Agreement between them by failing to pay royalties on certain “Licensed Product,” as defined in that License Agreement. Alphatec denied the allegations and asserted affirmative defenses
and counterclaims. 
 1.3. On January 14, 2011, Alphatec filed an action entitled Alphatec Spine, Inc. v. Biomet,
Inc., Case No. 11cv0089 JLS JMA in the United States District Court for the Southern District of California (“the ‘312 Patent Action”). On May 13, 2011, Alphatec filed a First Amended Complaint that named Biomet
Trauma, LLC and EBI, LLC as additional defendants. On June 2, 2011, Alphatec voluntarily dismissed Biomet, Inc. and Biomet Trauma from the case. 
 1.4. In the ‘312 Patent Action, Alphatec alleged that EBI infringed Alphatec’s U.S. Patent No. 5,290,312 (“the ‘312 patent”) by making, using, and selling certain
products, and that EBI actively induced infringement of the ‘312 patent by knowingly and intentionally causing others to infringe. EBI denied infringing the ‘312 patent and asserted affirmative defenses and counterclaims. 

1.5. The Actions, including (a) the Complaints, amended Complaint, the defenses and all counterclaims; (b) any and all issues
arising out of or relating to alleged breach of License Agreement and alleged infringement of the ‘312 Patent; and (c) any contemplated appeal arising from either the License Action or the ‘312 Patent Action, are collectively referred
to herein as the “Disputes.” 
 1.6. As of the Effective Date of this Settlement Agreement, the Parties have
reached an agreement on the terms of a complete and final resolution of the Disputes. 
 2. Agreement 

In consideration of the recitals above, and for other good and valuable consideration, the Parties agree to resolve any and all claims and
potential claims that the Parties may have against each other arising out of the Disputes before the Effective Date, whether known or unknown, 

 
suspected or unsuspected, and without conceding any wrongdoing. The Parties agree to the following: 
 2.1 Within three business days of the Effective Date, Alphatec will dismiss with prejudice the ‘312 Patent Action, and Cross will dismiss with prejudice the License Action. To the extent necessary,
the Parties’ counsel will provide any signatures or approvals required to effectuate such dismissals. 
 2.2 As of the
Effective Date, the Parties will enter into the Amended License Agreement attached as Exhibit A. 
 2.3 As of the Effective
Date, Alphatec will provide to EBI the covenant attached as Exhibit B, by which Alphatec covenants not to sue EBI (and its current parents, subsidiaries, affiliates, officers, directors, employees, customers, distributors, suppliers, representatives
and agents of any kind, and their successors and assigns) on U.S. Patent No. 5,290,312. 
 2.4 Within ten business days,
Alphatec will, and will cause its related entity, Scient’x SAS to, provide to Cross and EBI (and its current parents, subsidiaries, affiliates, officers, directors, employees, customers, distributors, suppliers, representatives and agents of
any kind, and their successors and assigns) a covenant not to sue on any rights of Alphatec or Scient’x SAS, including but not limited to any and all patent right held anywhere in the world, now or in the future, by Alphatec or Scient’x
SAS. This covenant not to sue will be in perpetuity, but will only apply to those products of Cross and EBI (i) that as of the Effective Date have clearance or approval to be marketed in the United States from the U.S. Food and Drug
Administration (or successor entity) (the “FDA”), or as of the Effective Date have obtained a CE mark approval, and (ii) are marketed or sold as of the Effective Date by Cross or EBI (the “Cross/EBI Protected Products”). The
foregoing covenant shall also apply to changes in materials, sizes, and other modifications made to Cross/EBI Protected Products, provided that such other modifications would not require a new regulatory filing, letter to file, or any other
communication with the FDA if the modified Cross/EBI Protected Product were to be marketed in the U.S. 
 2.5 Within ten
business days, Cross and EBI will provide to Alphatec (and its current parents, subsidiaries, affiliates, officers, directors, employees, customers, distributors, suppliers, representatives and agents of any kind, and their successors and assigns) a
covenant not to sue on any rights of Cross or EBI, including but not limited to any and all patent rights held anywhere in the world, now or in the future, by Cross or EBI. This covenant not to sue will be in perpetuity, but will only apply to those
products of Alphatec that (i) that as of the Effective Date have clearance or approval to be marketed in the United States from the FDA, or as of the Effective Date have obtained a CE mark approval, and (ii) are marketed or sold as of the
Effective Date by Alphatec or its current subsisiaries and affiliates (the “Alphatec Protected Products”). The foregoing covenant shall also apply to changes in materials, sizes, and other modifications made to Alphatec Protected Products,
provided that such other modifications would not require a new regulatory filing, letter to file, or any other communication with the FDA if the modified Alphatec Protected Product were to be marketed in the U.S. 

2.5 Except as otherwise provided for in the Amended License Agreement, each Party will bear its own fees and costs arising from the
License Action and the ‘312 Patent Action. 

  
 2 

 3. Mutual Releases 
 3.1 Except as to such rights or claims as may be created by this Settlement Agreement, each Party, on behalf of itself and its respective divisions, affiliates, parties, joint venturers, parents,
subsidiaries, predecessor and successor corporations, and past and present partners, directors, officers, shareholders, agents, servants, employees, representatives, assigns, heirs, successor in interest, predecessors in interest, administrators,
adjustors and attorneys, hereby releases, remises and forever discharges each other Party, including its respective divisions, affiliates, parents, subsidiaries, predecessor and successor corporations, and past and present partners, directors,
officers, shareholders, agents, servants, employees, representatives, assigns, heirs, successors-in-interest, predecessors-in-interest, administrators, adjustors and attorneys from any and all claims, demands, causes of action, obligations under any
implied covenant of good faith and fair dealing, damages and liabilities between the Parties heretofore or hereafter arising out of, connected with or incidental to the Disputes (the “Released Matter”). 

3.2 It is the intention of the Parties that this Settlement Agreement be effective as a full and final accord and satisfaction release of
each and every matter specifically or generally referred to in the Released Matter. 
 3.2.1 In furtherance of
this intention, each Party acknowledges that it may hereafter discover facts in addition to or different from those which it now knows or believes to be true with respect to the subject matter of this Settlement Agreement, but it is their intention
to fully and finally and forever settle and release any and all matters, disputes and differences, known or unknown, suspected or unsuspected, which do now exist, may exist or heretofore have existed between them which relate to the Released Matter.

 3.2.2. In furtherance of this intention, this release shall be and remain a full and complete general release,
notwithstanding the discovery or existence of any such additional or different facts. In particular, each Party hereby waives California Civil Code § 1542, which states: 
 “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE
MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.” 
 Each Party also hereby waives any and all
federal and state statutes similar in substance, meaning or application to California Civil Code § 1542. 

3.2.3 Each Party warrants and represents to each other Party that it has had the opportunity to consult with an attorney
regarding this Settlement Agreement and the effect and import of the release and waiver provisions above have been fully explained to each such Party. 

  
 3 

 4. Representations and Warranties 

Each Party represents and warrants to and agrees with the others as follows: 

4.1 The Parties have not been induced to enter into this Settlement Agreement by any representations and warranties made by any other
Party to this Settlement Agreement (other than such representations which are expressly contained in this Settlement Agreement). 
 4.2 The Parties have each had the opportunity to receive independent legal advice from attorneys of their choice with respect to the advisability of making the settlement and release provided herein and
of executing this Settlement Agreement. Before the execution of the Settlement Agreement, each Party and/or its attorney has reviewed the Settlement Agreement and has had the opportunity to negotiate revisions to the Settlement Agreement. Further,
each Party acknowledges, represents, and declares that it has carefully read this Settlement Agreement, knows the contents and executes the same voluntarily and without duress or pressure. 

4.3 There have been no other agreements or understandings between the Parties with respect to the Disputes with the exception of those
agreements and understandings memorialized in writing in this Settlement Agreement and its attachments, including the Amended License Agreement and the covenant not to sue. 
 4.4 Each Party has made such investigation of the facts pertaining to the Disputes, and all of the matters pertaining to them, as it deems necessary. 

4.5 Each Party is the sole and lawful owner of all rights, title and interest in and to every claim and other matter released in this
Settlement Agreement, and that no Party has assigned, granted or transferred in any way to any other person or entity any of claims, causes of action, costs or demands, or any part thereof, of the Released Matter. 

4.6 The Parties further agree to indemnify and hold each other harmless from: (i) any rights, claims, or causes of action that have
been assigned or transferred contrary to Section 4.5; and (ii) any and all loss, expense, and/or liability (including attorney fees) arising directly or indirectly from the breach of any of the foregoing representations or warranties
contained in Section 4.5. 
 4.7 The execution, delivery and performance of this Settlement Agreement have been duly
authorized by all requisite action on the part of such Party. 
 4.8 This Settlement Agreement constitutes legal, valid, and
binding obligations of such Party, enforceable against such Party in accordance with its terms. 
 4.9 Any individual signing
this Settlement Agreement on behalf of a corporation, partnership or trust has full authority to do so. 
 5. No Admission 

  
 4 

 This Settlement Agreement represents the settlement of disputed claims, and it does not
represent any admission of liability on the part of any Party, each of which expressly denies such liability. This Settlement Agreement may not be introduced into evidence or used in any action except in connection with an action to enforce the
terms of this Settlement Agreement. 
 6. Confidentiality 
 6.1 Except as set forth in Section 6.2, the Parties shall keep the terms of this Settlement Agreement confidential. 
 6.2 Notwithstanding Section 6.1, a Party may disclose: 

6.2.1 Anything that is, as of the Effective Date, already publicly available, including facts about the litigation, any
findings and holdings made in court orders, and historical facts revealed in court filings, court orders and rulings, or the Parties’ own press releases or regulatory filings. 

6.2.2 The fact, amount, and payment structure of the settlement, but only to the extent a Party determines that such
disclosure is required by law, including applicable securities rules and regulations. 
 6.2.3 The fact of the
settlement, including that as a result of the settlement Alphatec has waived its right to appeal any of the orders and rulings that the court made against it. 
 6.2.4(a) As may be otherwise required by applicable law, regulation, or order of a governmental authority of competent jurisdiction, provided that the disclosing Party shall, to the extent legally
permissible, provide the other Party with prior written notice of such applicable law, regulation, or order and, at the request of the other Party, use reasonable efforts to limit disclosure and to obtain a protective order or other confidential
treatment, (b) in confidence to the professional legal and financial counsel representing such Party, (c) in confidence to insurers or indemnitors, and (d) in confidence to any person or entity covered by the releases, licenses, or
covenants granted or referenced in this Settlement Agreement (and its Exhibits), provided that such person or entity is advised of the confidential nature of the disclosure and agrees to comply with this Section. 

6.2.5 Any confidential information, with the prior written consent of the other Party or Parties. 

6.3 Cross agrees not to make a public disclosure of the settlement before Alphatec does so. Before Alphatec’s public disclosure of
the settlement, Alphatec agrees to give Cross the opportunity to review and approve the language of the press release or other document making the disclosure, such approval by Cross not to be unreasonably withheld, conditioned or delayed.

  
 5 

 7. Miscellaneous 
 7.1 Severability. If any term or provision of this Settlement Agreement shall be found to be illegal or unenforceable, then, notwithstanding any such illegality or unenforceability, this Settlement
Agreement shall remain in full force and effect and such term or provision shall be deemed to be deleted. 
 7.2 Entire
Agreement. This Settlement Agreement constitutes the entire agreement of settlement and release among the Parties, and there are otherwise no other agreements expanding or modifying its terms. All prior oral and written agreements are expressly
superseded by this Settlement Agreement and are of no further force and effect. 
 7.3 Modification. The provisions of
this Settlement Agreement may be modified or amended only in a writing signed by each of the Parties that expressly states that modification or amendment of this Settlement Agreement is intended. 

7.4 No Waiver. No breach of any provision of this Settlement Agreement may be waived unless in writing signed by the Party against
whom a waiver is asserted. Waiver of any one breach shall not be deemed to be a waiver of any other breach of the same or any other provision. 
 7.5 Counterparts. 
 7.5.1 This Settlement Agreement may be
signed in counterparts and it shall be fully executed when signed by all Parties whether the signatures of all Parties appear on the original or one or more copies of this Settlement Agreement. 

7.5.2 The Parties agree to sign three (3) originals of this Settlement Agreement so that each Party will have a fully
executed original version of the Agreement. 
 7.6 Construction. Each Party to this Settlement Agreement has participated
in the drafting and preparation of this Settlement Agreement. Neither this Settlement Agreement nor any of its terms hereof shall be construed against the Parties or their representatives who have drafted the Settlement Agreement or any portion of
it. 
 7.7 Survival of Representations. All representations, warranties, and other agreements contained in this
Settlement Agreement shall survive the execution and delivery of this Settlement Agreement by all Parties. 
 7.8
Admissibility of Agreement. In any action or proceeding relating to this Settlement Agreement (including, but not limited to, actions or proceedings relating to the releases, conferred rights, or retained rights contained in this Settlement
Agreement), the Parties stipulate that a fully executed copy of this Settlement Agreement may be admissible to the same extent as the fully executed original of this Settlement Agreement. 

7.9 Captions. The captions or headings of the Sections of this Settlement Agreement are for convenience of reference only and in
no way define, limit, or affect the scope or substance of any Section of this Settlement Agreement 

  
 6 

 7.10 Notice and Cure. 

7.10.1 All notices and other communications among the Parties in connection with this Settlement Agreement shall be in
writing addressed to the following persons or Parties, and shall be deemed duly served, given and received (a) on the date of service, if served personally or sent by telex or facsimile transmission (with appropriate confirmation of receipt) to
the Party to whom notice is to be given, or (b) on the fourth day after mailing, if mailed by first class registered or certified mail, return receipt requested, postage pre-paid in the United States mail, or (c) on the next day if sent by
a nationally recognized courier for next day service and so addressed as follows: 
  

			
	If to Alphatec:	 	President and CEO, Alphatec Spine, Inc.
		
		 	 5818 El Camino Real

Carlsbad, CA 92008

		
	and	 	 General Counsel and SVP, Alphatec
 Spine, Inc.

		
		 	 5818 El Camino Real

Carlsbad, CA 92008

		
	If to Cross or EBI:	 	 Vice President Finance, EBI LLC,
 d/b/a Biomet Spine and Bone
 Healing

		
		 	 100 Interpace Parkway
 Parsippany, New Jersey 07054

		
	and	 	 Vice President and Division

Counsel, EBI LLC d/b/a Biomet
 Spine and Bone
Healing

		
		 	 100 Interpace Parkway
 Parsippany, New Jersey 07054

 7.10.2 The Parties, by like notice, may designate another or additional address(es),
facsimile number(s) or person(s) to which notices shall be given in connection with this Settlement Agreement. 

7.10.3 In the event that a Party believes that any other Party is in default or breach of any term of this Settlement
Agreement, the aggrieved Party shall give written 

  
 7 

 
notice of the default or breach by facsimile, personal service, overnight delivery by a nationally recognized courier, or first class registered or certified mail, return receipt requested, to
the other Party at the addresses identified below. Such other Party shall then have five (5) business days to rectify the alleged default or breach and shall provide written notice to the complaining Party of steps taken to rectify the alleged
default or breach (the “Cure Period”). The complaining Party shall withhold any legal action during the Cure Period, and to the extent that any alleged default or breach shall be cured within the Cure Period, the Parties agree to
treat such default or breach as though it had not occurred. 
 7.11 Governing Law, Choice of Forum, Costs and Fees.

 7.11.1 This Settlement Agreement shall be interpreted, construed, and enforced under and according to the laws
of the State of California, without regard to the choice of law rules of that or any other jurisdiction. Any action to enforce or interpret this Agreement must be filed exclusively in the Superior Court of Orange County or in the United States
District Court for the Central District of California, and the Parties agree that personal jurisdiction and venue are appropriate in those courts. 
 7.11.2 In any action brought to enforce or interpret this Settlement Agreement, or alleging the breach hereof, the prevailing Party shall be entitled to recover its expenses and costs, including but not
limited to actual attorneys’ fees. 
 [Signatures Follow] 

  
 8 

 IN WITNESS WHEREOF, the Parties have executed this Settlement Agreement as of the day and year below
written. 
  

							
	 	 	ALPHATEC SPINE, INC.
			
		 	By:	 	 /s/ Dirk Kuyper

		 	Its:	 	President and CEO
		 	Date: 12/30/11
		
	CROSS MEDICAL PRODUCTS, LLC	 	EBI, LLC
				
	By:	 	 /s/ Glen Kashuba
	 	By:	 	 /s/ Glen Kashuba

	Its:	 	President	 	Its:	 	President
	Date: 12/31/11	 	Date: 12/31/11

  
 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00200-of-00352.parquet"}]]